Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy

Journal of Viral Hepatitis

Volumn 15, Issue 2, 2008, Pages 115-119

  Freshwater, D A ^a   O'Donnell, K ^a   Mutimer, D J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Antiviral treatment; Ethnicity; Hepatitis C

Indexed keywords

ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAUCASIAN; DRUG RESPONSE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LEUKOCYTE COUNT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAMETER; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VIRUS LOAD;

EID: 37649018860     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00899.x     Document Type: Article

References (21)

1. Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. Am J Gastroenterol 2005 100 (3 716 722.
2. Gaglio PJ, Rodriguez-Torres M, Herring R et al. Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol 2004 38 (7 599 604.
3. Sterling RK, Hofmann CM, Luketic VA et al. Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? Am J Gastroenterol 2004 99 (5 866 872.
4. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep 2004 6 (1 66 70.
5. Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003 37 (4 795 801.
6. De MN, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002 49 (45 788 792.
7. Thio CL, Thomas DL, Goedert JJ et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001 184 (1 16 21.
8. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999 30 (3 787 793.
9. Barnes JS, Bennett CE. The Asian Population: 2000. Washington : US Census Bureau. 2002 Report No.: C2KBR/01-16.
10. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
11. Anonymous. Schering PEG-INTRON Phase IV trial to study African Americans. The Pink Sheet 2001 63 (5 16.
12. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
13. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
14. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004 117 (3 163 168.
15. Nguyen MH, Keeffe EB. Chronic hepatitis B and hepatitis C in Asian Americans. Rev Gastroenterol Disord 2003 3 (3 125 134.
16. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002 36 (5 1259 1265.
17. Celona AF, Yu MC, Prakash M, Kuo T, Bonacini M. Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol 2004 2 (6 459 462.
18. Kaba S, Dutta U, Byth K et al. Molecular epidemiology of hepatitis C in Australia. J Gastroenterol Hepatol 1998 13 (9 914 920.
19. Ostapowicz G, Dallinger M, Bell SJ et al. Changes in hepatitis C-related liver disease in a large clinic population. Intern Med J 2001 31 (2 90 96.
20. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 (2 518 526.
21. Snyder N, Gajula L, Xiao SY et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006 40 (6 535 542.